⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DRUG News
Bright Minds Biosciences Inc. Common Stock
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
globenewswire.com
DRUG
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
globenewswire.com
DRUG
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
globenewswire.com
DRUG
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
globenewswire.com
DRUG
Bright Minds Biosciences to Present at Upcoming Conferences
globenewswire.com
DRUG